# Natco Pharma Ltd (NATCOPHARM)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹1174.3
Day Change: +1.56%
52W High: ₹1226.8
52W Low: ₹789
Market Cap: ₹21,019 Cr

## Valuation
P/E: 13.5
P/B: 2.43
EPS: ₹86.93
Book Value: ₹482.88
Dividend Yield: 0.42%

## Returns
1Y Return: 41.59%

## Profitability
ROE: 0%
ROCE: 30.76%
Debt/Equity: 0.03
Revenue Growth: 36.3%
Profit Growth: 13.9%
EBITDA Margin: 39.11%
Operating Margin: 17.38%

## About
Natco Pharma Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Natco Pharma Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
- Announcement: Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
- BSE Filing: Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

## Access
Current tier: anonymous
More history: Register free to see 9 more years.

## Data Freshness
Quote Updated: 2026-05-21T20:00:03.547Z
Price History Updated: 2026-05-18T22:58:16.725Z
Latest Price History Date: 2026-05-18
Technicals Updated: 2026-05-18T22:58:16.725Z
Quant Updated: 2026-05-18T22:58:16.725Z
Sentiment Updated: 2026-05-18T22:58:16.725Z
Financials Status: current
Financials Updated: 2026-05-18T08:32:12.128Z
Financials Last Attempt: 2026-05-18T08:32:12.128Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2015)
Revenue: ₹739 Cr
Operating Profit: ₹179 Cr (OPM 24%)
Net Profit: ₹98 Cr
Tax: ₹129 Cr

## Annual P&L History
Mar 2015: Rev ₹739Cr | PAT ₹98Cr | OPM 24%
Mar 2016: Rev ₹825Cr | PAT ₹130Cr | OPM 25%
Mar 2017: Rev ₹1042Cr | PAT ₹156Cr | OPM 25%

## Balance Sheet (Mar 2015)
Total Assets: ₹1196 Cr
Total Liabilities: ₹1196 Cr
Borrowings: ₹240 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Venkaiah Chowdary Nannapaneni M. Pharm, MS., MD & Chairman
- Rajeev  Nannapaneni, CEO & Vice Chairman
- Donthineni Linga Rao M.D., President of Technical Affairs & Whole Time Director
- Chekuri Venkat Ramesh C.S., Company Secretary & Compliance Officer
- Potluri Sivaramakrishna Prasad, Executive VP of Corporate Engineering Services & Whole Time Director

---
Source: rupiya.io/stocks/natcopharm
Disclaimer: For research and education only. Not investment advice.